Stillhalter im Dax + anderen Werten

Verstehe was Du meinst: keine Earning-Trades, vor allem bei so einem "Risikowert". Aber die Gefahr kommt doch nicht von den Earnings sondern täglich von der Financial Times.

Tatsächlich halte ich die FT-Gefahr momentan für den Kurs für weniger relevant als schechte Zahlen, weil die würden nach all den "Jubelmeldungen" von WDI über die Supergeschäftslage m.M.n. dem Anleger schwerer im Magen liegen.
Allerdings habe ich für mich beschlossen, dass beides auf längere Sicht nicht wirkt, wenn die Aussichten verträglich sind.
Darum heute doch: open -WDI APR 110 P 3,95

Erstmal naked, wenn es die Tage noch eine günstige Absicherung gibt, kaufe ich die vielleicht dazu



LG

Ganz vergessen, 13.2. schon KHC - Call 35 Close (Kauf) zu 0,17 USD
(Open (Verkauf) damals zu 1,45 USD

Als Kombi aufgesetzt oder einzeln?
Bin am Überlegen, weiter hinten einzusteigen. April fände ich gut. Aber die Bilanzpressekonferenz liegt am 08.04.2020 und der Verfall am 17.04.
Wenn die Vola vorher hochkocht, wird aussteigen schwierig.



LG

Heute sagt mein Algo WDI kaufen! Ist aber kein ESG-Wert. Daher investiere ich nicht.

LG

OPEN

-GIS JUL 60 C 0,38
-GIS JAN 65 C 0,35

wichtige Entscheidung voraus

Ausübung J/N?

falls Ausübung, dann Versuch den short call zu rollen bis wertlos

heißt auch 8K (plus call) in ABBV zu stecken

aktuelle Situation

Möglichkeit
a) beide posi schließen ca. +200
b) +call ausüben und -call rollen bis..... (Invest 8K + call 10,35= 90,35)

short call liegt bei 11,37 + strike 85= 96,37 - aslo auch noch Aufgeld, Kurs 93,7 USD

Divis kommen im Mai + Aug 1,18

Investition in die nächsten Tagen

RTRX
Retrophin to Present at Upcoming Investor Conferences 26.02.

KK 16.75

Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam®, Thiola® and Thiola EC®.

SAN DIEGO, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (RTRX) today announced that on February 10, 2020, the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 22,500 shares of its common stock to three new employees and granted inducement restricted stock units, or RSUs, covering an aggregate of 8,000 shares of its common stock to seven new employees. These inducement stock options and inducement RSUs are subject to the terms of Retrophin’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Retrophin in accordance with Nasdaq Listing Rule 5635©(4).
The stock options have an exercise price of $16.80 per share, the closing price of Retrophin’s common stock on the date of grant, are non-qualified stock options, have a 10-year term and vest over four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the remaining 75% of the shares vesting in equal monthly installments over the following 36 months, subject to the new employee’s continued service relationship with Retrophin through the applicable vesting dates. 
The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Retrophin through the applicable vesting dates.



RCT laufen noch .....für
sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease.

Investition in die nächsten Tagen

RTRX
Retrophin to Present at Upcoming Investor Conferences 26.02.

KK 16.75

Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam®, Thiola® and Thiola EC®.

SAN DIEGO, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (RTRX) today announced that on February 10, 2020, the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 22,500 shares of its common stock to three new employees and granted inducement restricted stock units, or RSUs, covering an aggregate of 8,000 shares of its common stock to seven new employees. These inducement stock options and inducement RSUs are subject to the terms of Retrophin’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Retrophin in accordance with Nasdaq Listing Rule 5635©(4).
The stock options have an exercise price of $16.80 per share, the closing price of Retrophin’s common stock on the date of grant, are non-qualified stock options, have a 10-year term and vest over four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the remaining 75% of the shares vesting in equal monthly installments over the following 36 months, subject to the new employee’s continued service relationship with Retrophin through the applicable vesting dates. 
The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Retrophin through the applicable vesting dates.



RCT laufen noch .....für
sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease.

RESULTS

Retrophin to Report Fourth Quarter and Full Year 2019 Financial Results

SAN DIEGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2019 financial results on Monday, February 24, 2020 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Conference Call Information     

Date:
Monday, February 24, 2020
Time: 
4:30 p.m. ET

Luft nach oben!

Why History’s Longest Bull Market Is Just Getting Started

The current bull market started in February 2009, or 130 months ago. Since then, the S&P 500 has climbed 325% or 2.5% per month.
Again, this is the market’s longest period of growth in US history. But consider this for perspective: During the ’90s bull market, it only took the S&P 500 110 months to rise 325%. In other words, it reached this marker nearly two years faster.
This put the monthly return for the ’90’s bull market at nearly 3%. Meaning stocks rose 20% faster back then.
And then they kept going. After the initial 325% gain, stocks rose another 100% over the next 36 months:


https://www.etftrends.com/core-etf-chann...g-started/

aktuelle Situation

Möglichkeit
a) beide posi schließen ca. +200
b) +call ausüben und -call rollen bis..... (Invest 8K + call 10,35= 90,35)

short call liegt bei 11,37 + strike 85= 96,37 - aslo auch noch Aufgeld, Kurs 93,7 USD

Divis kommen im Mai + Aug 1,18

executed!

Investition in die nächsten Tagen

RTRX
Retrophin to Present at Upcoming Investor Conferences 26.02.

KK 16.75

Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam®, Thiola® and Thiola EC®.

SAN DIEGO, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (RTRX) today announced that on February 10, 2020, the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 22,500 shares of its common stock to three new employees and granted inducement restricted stock units, or RSUs, covering an aggregate of 8,000 shares of its common stock to seven new employees. These inducement stock options and inducement RSUs are subject to the terms of Retrophin’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Retrophin in accordance with Nasdaq Listing Rule 5635©(4).
The stock options have an exercise price of $16.80 per share, the closing price of Retrophin’s common stock on the date of grant, are non-qualified stock options, have a 10-year term and vest over four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the remaining 75% of the shares vesting in equal monthly installments over the following 36 months, subject to the new employee’s continued service relationship with Retrophin through the applicable vesting dates. 
The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Retrophin through the applicable vesting dates.



RCT laufen noch .....für
sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease.

Die Richtung stimmt schon einmal - nach rechts oben